cbdMD, Inc. YCBD

Reserveage, part of Twinlab, launches Longev+, a new supplement exclusive to The Vitamin Shoppe. The formula blends essential amino acids, HMB, creatine and resveratrol to support muscle health, recovery and everyday vitality for aging adults, offered in 20-count Mixed Berry stick packs. The move expands Reserveage’s presence in healthy aging and cellular wellness, packaged for on-the-go use. Twinlab CEO Anthony Zolezzi says Longev+ connects health aging heritage with an active lifestyle. CbdMD, Inc. has a previously announced definitive asset purchase agreement to acquire Reserveage and other Twinlab brands; the deal is subject to court approval and closing conditions. CbdMD CEO Ronan Kennedy notes the acquisition would pair Twinlab’s strengths with cbdMD’s marketing and operating infrastructure to support a broader wellness platform. Longev+ is exclusive to The Vitamin Shoppe and also listed on vitaminshoppe.com. Acquisition and portfolio expansion could materially affect cbdMD's growth trajectory if the deal closes.

cbdMD enters definitive agreement to acquire Twinlab Brands, expanding into legacy supplements, sports nutrition, women's beauty, weight loss and longevity wellness. Acquisition expands cbdMD into multiple new product categories as a major strategic move likely to alter trajectory and investor sentiment.

cbdMD Inc (YCBD) is executing a strategic pivot with cost cuts to improve performance, according to Q3 2026 earnings call highlights. Strategic pivot and cost cuts represent major moves likely to alter company trajectory and investor views.

cbdMD, Inc. posted 20% year-over-year revenue growth for the third fiscal quarter of 2026. 20% revenue growth signals improved financial results without indicating major strategic or competitive shifts.

cbdMD supports proposed Senate spending bill to protect access to full-spectrum CBD and naturally derived hemp products. Proposed bill would safeguard full-spectrum CBD access and support cbdMD market position.

cbdMD supports the Bipartisan Lawful Hemp Protection Act to safeguard consumer access to full-spectrum CBD and protect the hemp industry from restrictive regulations. Advocacy for hemp protection legislation offers potential regulatory tailwinds for cbdMD's core full-spectrum CBD products without guaranteeing immediate enactment or market shifts.

cbdMD, Inc. obtained self-affirmed GRAS determination for its broad spectrum CBD products, establishing a new safety standard. GRAS self-affirmation improves cbdMD product credibility and regulatory positioning in the CBD market.

cbdMD voiced support for White House push to ensure fair regulatory treatment of hemp-derived products. White House stance on hemp regulation may ease future compliance burdens and support cbdMD product sales.

cbdMD Inc (YCBD) management expresses optimism after March quarter results. Management optimism after quarterly results may lift short-term investor sentiment for YCBD.

cbdMD Inc (YCBD) reported strong sales growth in Q2 2026 earnings call highlights, navigating ongoing regulatory challenges. Strong sales growth despite regulatory hurdles represents a major positive shift in financial performance and investor outlook.

cbdMD, Inc. (YCBD) reported 19% year-over-year and 12% sequential revenue growth, with Bluebird acquisition integration and Medicare BEI Pathway positioning the company for continued momentum. Revenue growth, acquisition integration, and Medicare pathway access represent major strategic advancements boosting long-term trajectory and investor sentiment.

cbdMD, Inc. (YCBD) released its Q2 2026 earnings call summary covering financial results, operational updates, and outlook. Quarterly earnings data can shift short-term stock movement and investor views on performance.

cbdMD, Inc. reported Q3 2026 financial results on its earnings call, including revenue, net loss figures, and updates on operations and growth plans in the CBD sector. Quarterly earnings figures and forward guidance typically produce moderate short-term moves in share price and sentiment.

CbdMD, Inc. (YCBD) enabled unvalidated hemp gummies to enter Medicare through a backdoor loophole, imposing candy-coated costs on the federal program. Medicare billing scandal for unvalidated products invites federal investigations, fines, and potential business shutdown for cbdMD.

cbdMD, Inc. (YCBD) launches clinical healthcare channel to support first federal pathway for hemp-derived CBD in Medicare. Opening federal Medicare pathway for hemp-derived CBD represents major strategic expansion into regulated healthcare market.

cbdMD, Inc. releases Q1 2026 earnings call summary detailing quarterly financial results, operational updates, and forward-looking guidance. Q1 2026 earnings highlights financial performance and strategic outlook that significantly shape YCBD's trajectory and investor sentiment.

cbdMD Inc's Q1 2026 earnings call highlighted strategic acquisitions and financial improvements, signaling growth initiatives amid operational updates. Strategic acquisitions represent major moves poised to alter the company's trajectory and boost investor sentiment.

cbdMD, Inc. (YCBD) reported sequential revenue growth, improved liquidity, and a strong start to Fiscal 2026. Sequential revenue growth and improved liquidity indicate significant positive momentum for cbdMD's financial trajectory and market sentiment.

cbdMD, Inc. is expanding its Herbal Oasis product line into Louisiana through a partnership with Morales Beverage Group, building on the success experienced in Texas. This move aims to capitalize on the growing demand for CBD-infused beverages in new markets, enhancing the company's distribution and brand presence. The expansion into Louisiana represents a significant strategic move that could enhance market reach and revenue potential.

cbdMD, Inc. has enhanced its regulatory science platform to better support the evaluation of emerging cannabinoid pathways. This initiative aims to strengthen the company's position in the evolving regulatory landscape for cannabinoids, ensuring compliance and fostering innovation in product development. Strengthening the regulatory science platform is likely to significantly impact cbdMD's strategic positioning and compliance in a rapidly changing market.

cbdMD, Inc. (YCBD) has announced the strategic acquisition of Bluebird Botanicals, a move aimed at enhancing its product offerings and market presence in the CBD industry. This acquisition is expected to leverage Bluebird's established brand and customer base, positioning cbdMD for growth and increased competitiveness in the evolving market. The acquisition of Bluebird Botanicals is a significant strategic move that could enhance cbdMD's market position and financial performance.

cbdMD, Inc. (YCBD) reported its Q4 2025 earnings, highlighting strategic growth initiatives despite facing regulatory challenges in the CBD market. The company emphasized its commitment to expanding product lines and enhancing brand visibility while navigating the complexities of compliance. Management expressed optimism about future opportunities and outlined plans to leverage market trends to drive revenue growth. Investors were informed of ongoing efforts to strengthen partnerships and improve operational efficiencies, aiming to position cbdMD favorably in a competitive landscape. Strategic growth initiatives and regulatory challenges are likely to significantly impact the company's future performance and market positioning.

cbdMD, Inc. (YCBD) reported its third consecutive year of operating improvement, highlighting a strengthened balance sheet and compliance with NYSE American continued listing requirements. The company has made significant strides in its financial performance, which may enhance investor confidence and market positioning. The operating improvements and strengthened balance sheet are likely to significantly impact future performance and investor sentiment.

cbdMD, Inc. has successfully closed a private placement of Series C preferred stock, raising $2.25 million. The funds will be used to support the company's growth initiatives and enhance its product offerings in the CBD market. This financing round reflects investor confidence in cbdMD's strategic direction and operational capabilities. The capital raised will support growth initiatives and product development, which may moderately influence the company's financial performance.

cbdMD, Inc. has regained compliance with the NYSE American listing standards after addressing previous deficiencies. The company received a notice from the exchange in May 2023 regarding its stock price falling below the required minimum. Following corrective actions, cbdMD has successfully met the necessary criteria, allowing its shares to continue trading on the NYSE American. Regaining compliance with listing standards can stabilize investor confidence and support stock performance.

cbdMD, Inc. (YCBD) reported preliminary unaudited results for the fourth quarter and fiscal year 2025, indicating a significant increase in revenue compared to the previous year. The company highlighted growth in its direct-to-consumer segment and improvements in operational efficiency. Despite challenges in the broader market, cbdMD remains optimistic about its future prospects and strategic initiatives aimed at expanding its product offerings and market reach. The reported revenue growth and strategic initiatives suggest a significant impact on future performance and investor sentiment.

cbdMD, Inc. has expanded its Herbal Oasis brand by introducing new hemp-derived THC-infused social seltzers. This product line aims to cater to the growing demand for cannabis-infused beverages, enhancing the company's portfolio in the competitive market. The expansion reflects cbdMD's commitment to innovation and meeting consumer preferences for alternative beverage options. The introduction of new product offerings may moderately influence cbdMD's market positioning and financial performance.

cbdMD, Inc. has expanded its presence in Florida through a distribution partnership with Bevtalk, enhancing its market reach and product availability in the region. This collaboration aims to leverage Bevtalk's distribution network to promote cbdMD's range of CBD products, aligning with the company's growth strategy in the competitive CBD market. The partnership is expected to moderately influence cbdMD's market positioning and financial performance in Florida.

cbdMD, Inc. has successfully closed a $1.7 million Series B Preferred Private Placement, aimed at enhancing its financial position and supporting growth initiatives. The funding will be utilized for expanding product offerings and increasing market presence in the CBD sector. The funding will support growth initiatives and product expansion, which may moderately influence the company's financial performance and market positioning.

cbdMD, Inc. has launched Inferno Freeze, a new topical product designed to provide powerful relief for muscle and joint discomfort. This product features a unique formula that combines CBD with menthol and other ingredients to enhance its effectiveness. The company aims to expand its product line and meet growing consumer demand for high-quality CBD topicals. The introduction of a new product like Inferno Freeze may positively influence cbdMD's market positioning and financial performance, but its overall impact is expected to be limited.